Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | BCR | P11274 | 1/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.44 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4717327 | 0.87 | ABL1 (0.57) | ABL1BCRTRPV1FAAHKIF11 | |
| SCHEMBL1013500 | 0.82 | TRPV1 (0.45) | ABL1BCRTRPV1FAAHAAK1 | |
| SCHEMBL601224 | 0.81 | KMO (0.61) | FAAH | |
| SCHEMBL1011817 | 0.80 | ABL1 (0.51) | ABL1BCRTRPV1FAAHS1PR1 | |
| SCHEMBL2907264 | 0.79 | CYP1A2 (0.44) | FAAHAAK1 | |
| SCHEMBL18224103 | 0.79 | NPSR1 (0.40) | ABL1BCRAAK1KIF11 | |
| SCHEMBL1257940 | 0.79 | KMO (0.58) | FAAH | |
| SCHEMBL19219086 | 0.79 | KIF11 (0.68) | ABL1BCRTRPV1FAAHKIF11 | |
| SCHEMBL30268389 | 0.79 | ASIC3 (0.59) | ABL1BCRTRPV1FAAHAAK1 | |
| SCHEMBL12954522 | 0.79 | ABL1 (0.50) | ABL1BCRTRPV1FAAHKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118047763-A | Saturated nitrogen heterocyclic compound containing pyrimidine structure, and preparation method and application thereof | 贵州大学 | 2024-05-17 | — | — | CN | disclosed |
| EP-2900642-B1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2018-02-28 | — | — | EP | disclosed |
| CN-104684899-B | Substituted sulfonamide compounds | 霍夫曼-拉罗奇有限公司 | 2017-07-04 | — | — | CN | disclosed |
| US-9580411-B2 | Substituted sulfonamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-02-28 | — | — | US | disclosed |
| EP-2900642-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2015-08-05 | — | — | EP | disclosed |
| US-20150197509-A1 | SUBSTITUTED SULFONAMIDE SOLUTIONS | GENENTECH, INC. (US) | 2015-07-16 | — | — | US | disclosed |
| CN-104684899-A | Substituted sulfonamide compounds | HOFFMANN LA ROCHE | 2015-06-03 | — | — | CN | disclosed |
| WO-2015028989-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS ANTIMALARIAL AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-03-05 | — | — | WO | disclosed |
| US-8614201-B2 | Heterocyclic amides as modulators of TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-24 | — | — | US | disclosed |
| US-20120083474-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-05 | — | — | US | disclosed |
| US-20050267163-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-12-01 | — | — | US | disclosed |
| CN-1694873-A | Vanilloid receptor ligands and their use in treatments | AMGEN INC (US) | 2005-11-09 | — | — | CN | disclosed |
| EP-1562934-A1 | AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN | MERCK SHARP & DOHME LTD. (GB) | 2005-08-17 | — | — | EP | disclosed |
| EP-1546116-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | Amgen Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| EP-1542692-A1 | AMINO-PYRIDINE, -PYRIDINE AND PYRIDAZINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN | Amgen Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| WO-2004046133-A1 | AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN | MERCK SHARP & DOHME LIMITED (GB) | 2004-06-03 | — | — | WO | disclosed |
| US-20040082780-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2004-04-29 | — | — | US | disclosed |
| US-20040038969-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2004-02-26 | — | — | US | disclosed |
| WO-2004014871-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2003099284-A1 | AMINO-PYRIDINE, -PYRIDINE AND PYRIDAZINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN | AMGEN INC. (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197509-A1 | SUBSTITUTED SULFONAMIDE SOLUTIONS | TRPA1, TRPV1, TRPV5 | ABL1 1402/4885BCR 1371/4885TRPV1 2/4885 |
| US-20040038969-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | ABL1 1496/4885BCR 630/4885TRPV1 1/4885 |
| US-20050267163-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | ABL1 1443/4885BCR 587/4885TRPV1 1/4885 |
| US-20120083474-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | TRPA1, TRPV1, TRPV2 | ABL1 3488/4885BCR 3100/4885TRPV1 2/4885 |
| US-20040082780-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | ABL1 1502/4885BCR 667/4885TRPV1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.